PATENT CLAIM ANALYSIS

Application Number: 16424324
Application Type: Utility
Filing Date: 2019-05
Publication Date: 2019-10
Patent Classification: ["424", "181100"]

Abstract:
The present disclosure provides antibody drug conjugates that bind human cMET, their methods of making, and their uses to treat patients having cancer.

Claim (Index 138):
An anti-cMet antibody drug conjugate (\u201cADC\u201d), wherein the drug conjugate is monomethyl auristatin E (\u201cMMAE\u201d), and the ADC has the following structure: wherein Ab is an anti-cMet antibody comprising a VH chain comprising three CDRs, namely VH CDR #1 (SEQ ID NO:112), VH CDR #2 (SEQ ID NO:113) and VH CDR #3 (SEQ ID NO: 114); a VL chain comprising three CDRs, namely VL CDR #1 (SEQ ID NO: 115), VL CDR #2 (SEQ ID NO: 116) and VL CDR #3 (SEQ ID NO: 117); and a modified hinge region of SEQ ID NO: 170, n has a value ranging from 2 to 8, and attachment to the Ab is via a thioether linkage formed with a sulfhydryl group of a cysteine residue.

Metadata:
- Claim Count in Document: 67.0
- Percentile: 100.0
- Lexical Diversity: 1.08333
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15910788', '15363715', '15363786', '15819153', '14928738']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7010368211955067
- 35 USC 102 Novelty (BERT): 0.6130239872007233
- Combined Prediction Score: 0.6922355377960284
- Mean Citation Score: 369.40474200000006
- Max Citation Score: 555.21185
- Similarity Product: 486.9677705049694

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test